Browse > Article

The Efficacy of ZD1839 ($Iressa^{TM}$) in Patients with Advanced Non-small Cell Lung Cancer which has Progressed After Previous Chemotherapy  

Lee, Seung Whan (Department of Internal Medicine, Korea Cancer Center Hospital)
Kim, Duck Ryung (Department of Internal Medicine, Korea Cancer Center Hospital)
Lee, Sang Dae (Department of Internal Medicine, Korea Cancer Center Hospital)
Lee, Jong Sin (Department of Internal Medicine, Korea Cancer Center Hospital)
Park, Yeon Hee (Department of Internal Medicine, Korea Cancer Center Hospital)
Ryoo, Baek-Yeol (Department of Internal Medicine, Korea Cancer Center Hospital)
Kim, Heung Tae (Department of Internal Medicine, Korea Cancer Center Hospital)
Park, Sunhoo (Department of pathology, Korea Cancer Center Hospital)
Kim, Bong Seog (Department of Internal Medicine, Seoul Veterans Hospital)
Kim, Cheol Hyeon (Department of Internal Medicine, Korea Cancer Center Hospital)
Lee, Jae Cheol (Department of Internal Medicine, Korea Cancer Center Hospital)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.2, 2004 , pp. 160-168 More about this Journal
Abstract
Background : The role of second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) is known to be limited. Recently, ZD1839, the small molecule epidermal growth factor receptor-tyrosine kinase inhibitor, has been developed and has shown anti-tumor activity in patients with solid malignant tumors including lung cancer. We evaluated the response rate and toxicities of ZD1839 in patients with advanced NSCLC which has progressed after previous chemotherapy. Patients and Methods : We examined 83 patients with advanced NSCLC treated with ZD1839 for more than 1 month in Korea Cancer Center Hospital during the period from January 2002 to September 2003. All the patients were enrolled in the international expanded access program (EAP) with ZD1839 by AstraZeneca. The administered dose of ZD1839 was 250 mg once daily. Chest radiography and laboratory tests were followed-up. We evaluated the response rate, median survival, and toxicity after treatment. Results : Median age of the patients was 59 years (range 33-76). The most predominant cell type was adenocarcinoma and the most stage of the patients was IV. ECOG performance status was as follows; grade 0-1 in 10, grade 2 in 42, and grade 3 in 31 patients. Partial response was achieved in 12 patients (14.5%). Median overall survival was 9.2 (range 1.3-21.6+) months and median time to progression was 3.1 (range 1-21.2+) months. The most common adverse effect of ZD1839 was skin eruption which developed in 25 patients (25.8%). Significantly higher response rate and survival was found in patients with adenocarcinoma or good performance status. Conclusion : ZD1839 showed modest activity and tolerable toxicity in the treatment for patients with NSCLC which has progressed after previous chemotherapy.
Keywords
ZD1839; Non-small cell lung cancer; Epidermal growth factor receptor (EGFR);
Citations & Related Records

Times Cited By SCOPUS : 2
연도 인용수 순위
1 Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, et al. A retrospective analysis of the outcomes of patients who have received two prior chemotherapyregimens including a platinum and docetaxel for recurrent non-small-cell lung cancer. Lung cancer 2003; 39:55-61
2 Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70
3 Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839(Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63
4 Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21(12):2237-46
5 Pavelic K, Banjac A, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993;13:1133-7
6 Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and i combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002;29(suppl 4):37-46
7 Lilenbaum RC, List M, Desch C. A meta-analysis and the Cancer and Leukemia Group B randomized trial. Semin Oncol 1999;26:52-4
8 Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7(suppl4):2-8
9 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to Gefitinib. N Engl J Med 2004;350:2129-39
10 Paesmans M. Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer. Curr Opin Oncol. 2002;14:389-93
11 Rusch V, Baselga J, Cordon-Cardo C, Orazem J,Zaman M, Hoda S, et al. Differential expression of the epidermal growth factor receptor and its ligands inprimary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-85
12 Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadmini stration of ZD1839(Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92
13 Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lungcancer. N Engl J Med 2002;346:92-8
14 Rusch V, Klimstra D, Venkatraman E, Pisters PW,Langenfeld J, Dmitrovsky E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progressin. Clin Cancer Res 1997;3:515-22
15 Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogensis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indi cators of survival. Clin Cancer Res 1998;4:241-9
16 LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res2003;9:2040-8
17 Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Duphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62
18 Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8
19 Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidemal growth factor receptor tyrosine kinase, in symtomatic patients with non-small cell lung cancer; a randomized trial. JAMA 2003;290: 2149-58
20 Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy. Cancer Res 2002;62:5749-54
21 Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65
22 Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998;77:663-9